Records 1 - 5
| Effects of ABCG2 and SLCO1B1 gene variants on inflammation markers in patients with hypercholesterolemia and diabetes mellitus treated with rosuvastatin.
European journal of clinical pharmacology 2020 May .
Zhang Dan, Ding Yangming, Wang Xiaoxue, Xin Wenyu, Du Wenwen, Chen Wenqian, Zhang Xianglin, Li Pengm
| Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Drug metabolism and pharmacokinetics 2019 Aug .
Lee Nora, Maeda Kazuya, Fukizawa Shinya, Ieiri Ichiro, Tomaru Atsuko, Akao Hironobu, Takeda Kenji, Iwadare Mizuho, Niwa Osamu, Masauji Tougen, Yamane Naoe, Kajinami Kouji, Kusuhara Hiroyuki, Sugiyama Yuic
| Polymorphisms of uric transporter proteins in the pathogenesis of gout in a Chinese Han population.
Genetics and molecular research : GMR 2015 14 (1): 2546-50.
Wan W, Xu X, Zhao D B, Pang Y F, Wang Y
| Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.
Pharmacogenomics 2013 Aug 14 (11): 1283-94.
Lee Hon-Kit, Hu Miao, Lui Sandra Sh, Ho Chung-Shun, Wong Chun-Kwok, Tomlinson Bri
| ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.
Clinical pharmacology and therapeutics 2010 May 87 (5): 558-62.
Tomlinson B, Hu M, Lee V W Y, Lui S S H, Chu T T W, Poon E W M, Ko G T C, Baum L, Tam L S, Li E